Bindarit (AF2838) is a naturally derived compound with selective anti-inflammatory activity by inhibiting the monocyte chemotactic protein (MCP) subfamily, including MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8; it demonstrates therapeutic potential in lupus nephritis by delaying proteinuria onset, protecting against renal damage, and prolonging survival in NZB/W mice; it suppresses tumor growth and macrophage infiltration in melanoma models; it reduces neointima formation in vascular injury models by inhibiting vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, as well as decreasing macrophage content in neointimal lesions; it inhibits metastatic progression in prostate cancer (PC-3M-Luc2) xenograft models and impairs primary tumor formation in breast cancer (4T1-Luc) models; it significantly reduces tumor-associated macrophage and myeloid-derived suppressor cell infiltration in primary 4T1-Luc tumors.